ADC Summit 2026

Welcome to the ADC Summit 2026, where biopharma leaders, ADC innovators, and key partners unite to develop, manufacture, and advance antibody-drug conjugates from promising assets to meaningful patient impact.

The ADC field is entering a new phase of clinical acceptance, as programs demonstrate efficacy across tumor types and treatment settings. However, managing toxicity remains essential, requiring careful patient selection to balance benefit and tolerability. The next wave advances through molecule design, linker and payload strategies, precise conjugation, biomarker-based selection, and manufacturing.

Join us to gain insights, connect with industry leaders, and help shape scalable ADC development that drives real patient benefit.

Engineering ADC chemistry to enhance therapeutic index and outcomes

Learn how conjugation strategies, innovative linker design, and selective payload choices enhance ADC stability, reduce off-target toxicity, and improve efficacy.

ADC manufacturing and supply chain solutions for large-scale production

Explore practical strategies to scale ADC production, enhance analytical characterization, and minimize supply disruptions of critical components.

Building clinical and regulatory readiness for successful ADC development

Map clinical and regulatory strategies that strengthen ADC submissions and approvals through trial design, dosing strategy, bioanalysis, and risk control.

Bispecific and multispecific ADCs to counter tumor heterogeneity

Understand how dual- and multi-target ADCs overcome antigen escape and tumor heterogeneity while balancing uptake and developability for clinical translation.

Reducing ADC toxicity through predictive modeling and mitigation strategies

Discover how predictive systems and preclinical models identify ADC toxicity, and how mitigation strategies enhance tolerability across treatment regimens.

Strategies to overcome ADC resistance and extend therapeutic efficacy

Evaluate resistance mechanisms and countermeasures, including payload design, target strategy, sequencing, and combinations, to sustain benefit in solid tumors.

Expert Speakers

Past Attendees

hidden text

hidden text